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1. Introduction 
Recent microarray technology and bioinformatics have shown the ability of analysing 
oncogenic cellular signalling pathways based upon gene signatures in cancers. (Bild et al., 
2006; Dressman et al., 2007; Gatza et al., 2010) Epithelial ovarian cancer (EOC) is the most 
important cause of mortality among gynaecological cancers. Patients with EOC often 
present in an advanced stage. Treatment modalities consist in general of the sequence of 
surgical cytoreduction and platinum-taxane based chemotherapy. (Cannistra, 2004) 
Although the disease is relatively sensitive to cytotoxics, relapses occur in a majority of 
patients with advanced stage. (Cannistra, 2004) The emergence of resistance to conventional 
chemotherapeutics is an often-deadly event in the management of ovarian cancer patients. 
There is an urgent need for additional therapies that increase survival and/or quality of life 
in these patients.  
The objective of our study was to look for cellular pathways that have an effect on survival 
outcome by a bioinformatical approach. (Trinh et al., 2011) These pathways may guide us to 
find interesting targets in ovarian cancer. Survival can be used as a measure to quantify the 
biological relevance in this disease. Ideally, evaluation of survival outcome should be made 
in a homogenous population with a uniform treatment to avoid treatment-induced biases 
and uniform histology to find subtler differences independent from histology.  Another 
methodology of estimating prognostic value may be the correlation with documented 
prognostic gene signatures that have shown to be of prognostic value in breast cancer and 
other types of cancer. The invasiveness gene signature (IGS) was generated using stem cell-
like or tumorigenic breast cancer cells.(Liu et al., 2007) This signature has shown prognostic 
value in lung cancer, medulloblastoma and prostate cancer. The Wound healing response 
(WHR) signature, based upon genes induced by wound healing, also has shown its 
prognostic value in breast cancer, NSLC and bladder cancer. (Chang et al., 2005; Lauss, 
Ringnér, & Höglund, 2010; Mostertz et al., 2010) The genomic grade index (GGI) is a 
signature that divides low-grade versus high-grade breast carcinomas. (Sotiriou et al., 2006) 
Interestingly, using this signature, histological intermediate-grade tumours could be 
classified as low- or high-grade tumours with the preservation of the gene signatures’ 
prognostic value.  
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2. Oncogenic pathways 
The oncogenic gene signatures were derived from a recent paper by Gatza and colleagues 
and applied similarly. (Gatza et al., 2010) These pathway signatures were mainly generated 
by activating or silencing specific genes in cell lines experiments. The signatures were 
robustly validated afterwards. For each pathway, a pathway activation score was calculated 
based upon the gene signature to quantify the activation by a score.  
Briefly, for each array-sample the pathway-specific informative genes were identified. Next 
a pathway score was calculated by adding up the products of the gene expression for each 
gene and its corresponding regression coefficient, which indicates the weight (amplitude of 
regression coefficient) and the effect (sign of regression coefficient) of the corresponding 
gene for activation of the corresponding pathway. Finally, the pathway scores were scaled 
using the intercept values provided in the original manuscript and standardized for 
comparability by median-centering and setting the standard deviation to 1. Pathways 
included in the analysis were AKT, ┚-Catenin, E2F1, EGFR, ER, HER2, INF┙, INF┛, MYC, 
p53, p63, PI3K, PR, RAS, SRC, STAT3, TNF┙, and TGF┚. 
Since PARP inhibitors and VEGF-A inhibitors have shown promising results in ovarian cancer, 
the BRCA pathway and VEGF-A pathway was also studied. (Audeh et al., 2010; Burger et al., 
2010; Fong et al., 2009; 2010) For the BRCA signature, we used one that was published by 
Konstantinopoulos and colleagues. (Konstantinopoulos et al., 2010) For a VEGF-A signature 
we have used and validated genes that were reported by Hu et al. (Hu et al., 2009) A BRCA 
activation score was applied using the same methodology with 60 genes, their weight and 
sign. (Konstantinopoulos et al., 2010) Prognostic gene signatures (IGS, GGI and WHR) were 
also applied by previously described methodology. (Chang et al., 2005; Liu et al., 2007; Sotiriou 
et al., 2006) All gene signature activation scores were handled as a continuous variable. The 
same standardisation (Median=0; SD=1) was applied for each gene signature. 
For the VEGF-A activation signature we used the 13 genes reported by Hu and colleagues. 
(Hu et al., 2009) To validate and transform this gene signature into a VEGF-A activation 
probability score we performed subsequent analysis using publicly available gene 
expression data sets on naïve and VEGF-A treated HUVEC cell lines (GSE18913 (N=21), 
GSE10778 (N=9; only the HGU133A samples were used) and GSE15464 (N=4)). Each data 
set was normalised using the GC-RMA algorithm and informative genes (above log 2(100) 
in at least 25% of the genes) were filtered in. First, we applied a principal component 
analysis on the GSE18913 data set using the informative VEGF-A signatures genes only 
(N=10). Only 10 out of 13 genes (FABP5, UCHL1, PLOD, DDIT4, VEGF, ADM, ANGPTL4, 
NDRG1, NP and SLC16A3) were reliably measured (high signal-to-noise ratio). Using these 
10 genes in a principal component analysis (PCA) we were able to demonstrate a significant 
segregation of VEGF-A treated and naïve HUVEC’s along the first principal component. 
Class label permutation analysis revealed that the observed Euclidean distance between the 
centroids of the VEGF-A treated and naïve HUVEC’s on the 2D scatterplot representation of 
the PCA was significantly different from the expected Euclidean distance (Figure 1A; 
Observed Euclidean distance=2.185, Expected Euclidean distance=0.682, P<0.0001).  
Next, we transformed the VEGF-A signature into a VEGF-A activation probability score 
adopting the methodology described by Gatza and his colleagues. (Gatza et al., 2010). 
Therefore, we used the regression coefficients that define the first principal component and 
multiplied these with the gene expression values of their corresponding genes. The products 
were summed and the resulting score was compared between VEGF-A treated and naïve 
HUVEC’s using a Mann-Whitney U-test (Median VEGF-A treated HUVEC’s: 6.416, Median 
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naïve HUVEC’s: 4.276, P<0.0001). The boxplot representation is provided in Figure 1B. In 
addition, we observed a strong correlation between the VEGF-A activation probability 
scores and the time of VEGF-A incubation of HUVEC’s (Correlation coefficient = 0.762; 
P=0.038). (Figure 1C). To validate our procedure, we applied our algorithm on the samples 
in gene expression data sets GSE10778 and GSE15464.  
 
 
 
Fig. 1. Principal Component Analysis Plot (A) segregates VEGF-A treated cells versus 
untreated cells. The calculated activation scores were higher in treated cells versus untreated 
cells in an apparent time dependent way. (B+C) 
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Fig. 2. Validation of the VEGF-A activation score methodology in data derived from two other 
experiments. The activation scores of VEGF-A treated cells were higher than the untreated 
condition (red dot). The higher activation scores were observed for VEGF-A treated cells but 
not for EGF treated cells, suggesting he specificity of the activation score for VEGF-A. 
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3. Patient datasets 
A dataset of 285 patients (Melbourne dataset) was obtained though the Gene Expression 
Omnibus GEO database (GSE 9891) together with the clinical annotation data file. Only 
patients that had carcinomas of serous histology in advanced stages (III/IV) were 
included for analysis. Patients were selected that received platinum and taxane based 
chemotherapy. Other patients who did not receive chemotherapy or received only one 
agent, platinum or taxane, were also excluded. After this selection N=165 patients were 
eligible for further analysis. This dataset contained gene expression data derived from the 
Affymetrix U133_plus2 platform, which already underwent normalisation using the 
Robust Multiarray Averaging (RMA) method and subsequent filtering by excluding log 
expression values of <7 and a variance of <0.5. After filtering there were 8,732 probe sets 
left that are considered informative. Progression free survival was used in further 
analysis. (Tothill et al., 2008) 
A second dataset GSE3149 N=153 (North Carolina dataset) with clinical data was also 
obtained from the GEO website. Here, the same criteria for patient selection were used. 
After selection N=107 were further analysed. The North Carolina dataset used the same 
Affymetrix U133_plus2 platform. The raw data were processed in Bioconductor in R 
software packages. Filtering was done by selecting expressions below a threshold (log 2 of 
100) that are present in at least 25% of the arrayed samples. Normalisation was done using 
GC-Robust Multiarray Averaging. The number of probe sets that were informative was 
7,741. Overall survival data was used, as there was no progression free survival data 
available. (Bild et al., 2006) A third dataset (Québec dataset) were patients (N=20) that were 
selected to be either chemoresistant versus chemosensitive. Here, raw microarray data based 
upon the Agilent platform Human 1A (v2) oligonucleotide microarray were normalised 
using the Lowess normalisation method. Hereafter, 16,096 genes were eligible for further 
analysis. Progression free survival data were used. RAW gene expression data is publicly 
available according to MIAME guidelines through the GEO database (Accession number: 
GSE 28739). (Bachvarov et al., 2006) A fourth dataset (Niigata Dataset-GSE 17260) contained 
samples that originated from patients who met the inclusion criteria from present study. 
Progression free survival data were available. The authors used the Agilent Whole Human 
Genome Oligo Microarray platform and normalised the data using upper quartile 
normalisation. 28,446 genes were found to be informative. (Yoshihara et al., 2010) A fifth 
and sixth dataset (Boston dataset A +B - GSE19829) were derived from a report studying 
BRCAness in ovarian cancer. (Konstantinopoulos et al., 2010) Progression free survival data 
was used. After selection, (N=26) and (N=36) patients were eligible. These datasets were 
RMA-normalised. 35252 and 5626 probe set ID’s were informative after filtering. Gene 
expression data was derived from two platforms: the Affymetrix U133_plus2 platform and 
the Affymetrix 95UAv2.  
4. Correlation of pathway activation scores with prognostic signatures 
We applied the oncogenic pathways on the six datasets. These datasets together represent a 
total of N=464 advanced serous papillary carcinomas. A summary of these 6 datasets is 
listed in Table 1. Since these are selected oncogenic pathways, it is plausible that many 
significant correlations were found between pathway activations and the 3 prognostic 
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Dataset N=464 Platform  
Norma-
lisation  
Clinical 
outcome 
Uniform 
treat-
ment 
Advanced 
stage/ serous 
papillary 
histology 
Québec 2006 20 
Agilent 
Human 1A 
(v2) 
Lowess PFS yes yes 
North 
Carolina 
2006 
107 
Affymetrix 
U133_plus2 
GC-
RMA 
OS yes yes 
Melbourne 
2008 
165 
Affymetrix 
U133_plus2 
RMA PFS yes yes 
Niigata 2010 110 
Agilent Whole 
Human 
Genome Oligo 
Microarray 
Upper 
quartile 
PFS yes yes 
Boston A 
2010 
26 
Affymetrix 
U133_plus2 
RMA PFS yes yes 
Boston B 
2010 
36 
Affymetrix 
U95_A2 
RMA PFS yes yes 
Table 1. A summary of datasets that were used in the meta-analysis.  
 
Pearson Rho WHR IGS GGI 
Québec 0.65 0.62 0.67 
 p=3.4 E-4 p=0.001 p=2.0 E-4 
North Carol 0.81 0.89 0.6 
 p=7.7 E-40 p=9.9 E-59 p=8.0 E-18 
Melbourne 0.73 0.54 0.79 
 p=2.8 E-22 p=6.9 E-11 p=5.6 E-28 
Niigata 0.77 0.73 0.79 
 p=2.4 E-19 1.0 E-22 p=4.5 E-25 
Boston A 0.83 0.48 0.87 
 p=1.2 E-7 p=0.013 p=5.5 E-9 
Boston B 0.75 0.56 0.26 
 p=1.8 E-7 p=3.7 E-4 p=0.13 
Meta Analysis 0.73 0.62 0.79 
 p<0.0001 p<0.0001 p<0.0001 
Table 2. This shows the consistent correlations of the ┚-Catenin activation scores and 
WHR/IGS/GGI in each separate dataset (Québec, North Carolina, Melbourne, Niigata, 
Boston A and Boston B dataset). Overall Rho Coefficients were estimated by a meta-analysis 
approach using random models effects.  
www.intechopen.com
 
Oncogenic Pathway Signatures and Survival Outcome 
 
111 
signatures (IGS, WHR and GGI). The ┚-Catenin pathway showed consistent and strong 
correlations. (Table 2) Since the six datasets were generated on different platforms with 
different methodologies, we estimated the overall effect of a pathway activation score by using 
a meta-analysis approach (Table 2). Similar meta-analysis of correlation coefficients showed 
that the BRCA, E2F1, EGFR, HER2, MYC, p53, p63 and PI3K showed steady correlations with 
the WHR, GGI and IGS. The RAS pathway and TGF┚ pathway showed significant correlations 
with 2/3 prognostic signatures. Table 3 shows the overall correlation estimates, which were 
the most significant. While most pathway activation scores showed a positive correlation, the 
EGFR, HER2, p53 and TGF┚ pathway showed a negative correlation. 
 
 
Rho estimates WHR IGS GGI 
    
-Catenin 0.73 0.62 0.79 
 p<0.0001 p<0.0001 p<0.0001 
BRCA 0.43 0.36 0.36 
 p<0.0001 p<0.0001 p<0.0001 
E2F1 0.51 0.42 0.54 
 p<0.0001 p<0.0001 p<0.0001 
EGFR -0.52 -0.43 -0.42 
 p<0.0001 p<0.0001 p<0.0001 
HER2 -0.45 -0.5 -0.26 
 p<0.0001 p<0.0001 p<0.0001 
MYC 0.69 0.53 0.4 
 p<0.0001 p<0.0001 p<0.0001 
p53 -0.59 -0.42 -0.72 
 p<0.0001 p<0.0001 p<0.0001 
p63 0.46 0.29 0.36 
 p<0.0001 p=0.001 p<0.0001 
PI3K 0.43 0.33 0.29 
 p<0.0001 p<0.0001 p=0.002 
RAS 0.51 0.2 0.4 
 p<0.0001 p=0.017 p<0.0001 
TGF -0.23 -0.3 -0.13 
 p=0.0001 p<0.0001 p=0.004 
Table 3. Estimates of Pearson rho correlation coefficients after meta-analysis of six datasets 
between pathway activation scores and prognostic gene signatures: wound healing response 
signature (WHR)/ Invasiveness gene signature IGS and Genomic grade Index (GGI). Most 
significant correlations are shown. (Threshold p-value adjusted for multiple testing=0.0025) 
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5. Association of pathway activation scores with survival outcome 
While some pathways were associated with survival outcome in one or more datasets, they 
showed no or opposite result in another dataset. To estimate the overall survival effect of a 
given pathway, a similar meta-analysis approach was performed to estimate the overall 
 
 
Fig. 3. Forest plots of meta-analysis using a random effects model of the ┚-Catenin BRCA, 
E2F1, p63, PR, PI3K, RAS and VEGF pathway.  
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effect of pathway activation using a random effects model. After this analysis, the ┚-Catenin, 
E2F1, PR, p63 PI3K and RAS pathway activation showed a significant association with 
clinical outcome. Considering the overall effect by means of Hazard Ratios, the ┚-Catenin 
pathway showed the most prominent effect after meta-analysis (HR= 0.74; 95%CI [0.62-
0.88]). The survival analysis showed that the higher the activation of the ┚-Catenin pathway, 
the better the outcome was. Also for PR, E2F1, RAS, PI3K and p63 increased activation of 
respective pathway was associated with more favourable survival.  
Because of these rather unexpected results, we calculated the activation scores of selected 
discovered pathways in other independent datasets as additional quality control to confirm 
whether the directions of the activation scores were certainly correct. For ┚-Catenin the  
For the 3 prognostic signatures there was a tendency that a prognostic worse outcome 
predicted by IGS, WHR and GGI showed an unexpected higher probability of better clinical 
survival outcome. Further analysis in the Québec dataset showed that chemoresistant 
patients showed significant lower scores than chemosensitive patients and therefore may 
explain this finding.  
 
 
Fig. 4. In the Québec dataset sensitive (S) patients showed a higher genomic grade index 
(GGI) compared to chemoresistant patients (R) (p=0.002). Similarly chemosensitive patients 
showed a higher wound healing response score (p=0.02) and a higher invasiveness gene 
signature score (IGS) (p=0.06). 
6. Discussion 
Our initial analysis consisted of two datasets. The initial design was to use one dataset, as a 
discovery dataset while the other one would serve as a validation set. Since bioinformatical 
mislabelling errors/reproducibility issues have lead to withdrawal of papers of the same 
research group from which one dataset originated, we sought additional datasets to confirm 
our findings and render more power and reliability. (Bonnefoi et al., 2011; Potti et al., 2011) 
Furthermore, this research group and critical review by another research group have 
confirmed that the dataset that was used in the present meta-analysis was indeed correctly 
annotated. (Baggerly, Coombes, & Neeley, 2008; Dressman et al., 2007) With the availability 
of more datasets, we noticed variation among pathway’s association with survival outcome. 
We therefore used a meta-analysis approach to estimate the overall effect. The advantage is 
that several studies can be combined despite differences in platforms and methodologies. 
This overall effect estimation takes into account the number of patients of each separate 
dataset and confidence interval in the estimation of correlation coefficient of survival hazard 
ratios. The heterogeneity among datasets (e.g. different patient selection criteria) may partly 
explain some opposite findings. The Québec dataset is different from others because this 
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specifically selected patients to study differential expression between chemosensitive versus 
chemoresistant tumours. (Bachvarov et al., 2006) This dataset therefore may represent the 
extremities of this disease. Interestingly this dataset showed clearly that chemosensitive 
patients had tumours that were more likely to be of unfavourable outcome estimated by 
WHR/IGS/GGI. This contradictory finding may be explained by the finding that these three 
prognostic signatures are all primarily associated with increased proliferation. (Wirapati et 
al., 2008) It is known that chemosensitive tumours have higher tumour cell proliferation 
indexes in serous ovarian cancer. (Itamochi et al., 2002; Têtu et al., 2008) The estimated 
prognostic values in this survival analysis therefore seems strongly oppositely confounded 
by the predictive value for platinum/taxane-based chemotherapy.  
Despite the heterogeneity in datasets and confounding of predictive value versus prognostic 
value, the E2F1, ┚-Catenin and the PI3K activation scores showed overall association with 
survival outcome (p<0.01) and consistent significant correlations with three prognostic 
signatures. 
 
 
Fig. 5. A Venn diagram is showing combined results of the meta-analysis: ┚-Catenin, E2F1, 
p63 and PI3K activation scores showed significant association with survival and were 
significantly correlated with all three prognostic signatures (WHR/IGS/GGI) after meta-
analysis. PR and RAS activation scores were associated with clinical outcome, but did not 
consistently correlate with prognostic signatures. *Negative correlation coefficient  
**borderline significance with clinical outcome 
The E2F1 pathway a critical role in proliferation and apoptosis. It has been shown that 
transcription factor E2F1 interacts with the p53 and PI3K pathway. (Hallstrom, Mori, & 
Nevins, 2008; Reimer et al., 2006; 2007) Its role in ovarian cancer has been unclear, as other 
research groups have found similar favourable survival with increased E2F1 pathway 
activation (Hallstrom et al., 2008), while other findings have shown favourable survival with 
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decreased E2F1 gene expression by RT-PCR. (Reimer et al., 2006; 2007) It must be remarked 
that the latter study included an overrepresentation of patients with clear cell carcinomas 
(42.9%) and may be less informative here.  
The ┚-Catenin protein is a multifunctional protein. It was originally discovered as a protein 
that is associated with the cytoplasmatic region of E-cadherin. E-cadherin is a 
transmembrane protein that is involved in cell-cell contact and cell’s adhesive functions. 
Furthermore, ┚-Catenin is involved in Wnt signalling as a nuclear transcription factor and is 
believed to play a role in cancer stem cells. (Nusse, 2008) Loss of its membranous function or 
a higher nuclear presence has been linked with poor survival in several studies in ovarian 
cancer based upon immunohistochemical studies. (Faleiro-Rodrigues et al., 2004; Faleiro-
Rodrigues, Macedo-Pinto, Pereira, & Lopes, 2004; Irving et al., 2005; 2005; Rosen et al., 2010; 
2010; Stawerski et al., 2008; Stawerski, Wagrowska-Danilewicz, Stasikowska, Gottwald, & 
Danilewicz, 2008; Voutilainen et al., 2006; 2006) In addition, a correlation of ┚-Catenin 
protein expression has been described with tumour grade and Ki-67 expression. (Stawerski 
et al., 2008; Voutilainen et al., 2006) Present results are thus confirmative of earlier findings 
that ┚-Catenin is associated with survival outcome. The consideration must be made 
whether this effect is not attributed to its predictive value to platinum-taxane chemotherapy 
rather than its prognostic value. In present study, ┚-Catenin had strong and consistent 
correlation with IGS/WHR/GGI. Although these signatures were constructed based upon 
different oncogenic biological processes (wound healing, stem cell phenotype, grade), their 
major common force has been proven to be cell proliferation. (Wirapati et al., 2008) The 
observation that chemosensitive patients in present analysis showed significantly higher 
values of GGI, WHR and IGS renders credibility to this statement.  
Similarly, the unexpected findings that increased activation of PI3K-, and RAS- pathways 
are more favourable for survival may be explained by their predictive value for 
chemotherapy. This hypothetically may have clinical consequences. Several compounds 
target the PI3K pathway or downstream effectors (e.g. mTOR) and are under early clinical 
development in epithelial ovarian cancer. Other compounds have inhibitory effects on the 
RAS pathway, e.g lonafarnib (a farnesyltransferase inhibitor). Recent findings of a 
randomised phase II trial (IGCS meeting 2010, W. Meier et al.) showed that the concomitant 
addition to standard chemotherapy (first line) and 6-month continuation of lonafarnib in 
primary epithelial ovarian cancer stage IIB-IV (n=105) resulted in borderline poorer outcome 
for the experimental- lonafarnib arm (overall survival HR=0.62 95CI%(0.36-1.06) p=0.08) or 
even resulted in significant unexpected worse outcome (p=0.01) in the experimental stratum 
of patients with suboptimal debulking. This finding may be relevant in the context of our 
results. Since increased activation of pathways as RAS and PI3K have been found to be 
favourable for survival outcome, the question should be asked whether inhibition of one of 
these pathways concomitant with chemotherapy is desirable. These pathways are driving 
forces of proliferation, which is an important factor in the efficacy of standard 
chemotherapeutics. We hypothesize that inhibition of these pathways may therefore also 
negatively affect the efficacy of these chemotherapies and theoretically induce 
chemoresistance. This would possibly be an explanation for the recent unexpected findings 
of lonafarnib in ovarian cancer. Hence, we theorize that these agents may have their 
potential in ovarian cancer in a sequential adjuvant setting rather than its concomitant 
combination with chemotherapy.  
The PR pathway did not show any relevant association with IGS or GGI. It did show high 
significant association with survival outcome and WHR. Other immunohistochemical 
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studies have shown that the PR protein expression has predictive of prognostic value, more 
than the expression of ER. (Hah et al., 2011; Høgdall et al., 2007; Tangjitgamol, 
Manusirivithaya, Khunnarong, Jesadapatarakul, & Tanwanich, 2009; X.-Y. Yang, Xi, K.-X. 
Yang, & Yu, 2009) Since PR expression is a downstream target of the ER pathway, this 
finding may indicate that an active ER pathway, rather than the expression of ER by itself 
may be of importance. Anti-hormonal therapies have shown anti-tumoural activity in 
relapsed/refractory ovarian cancer in phase II studies. (del Carmen et al., 2003; 
Papadimitriou et al., 2004; Smyth et al., 2007; C. J. Williams, 2001; C. Williams, Simera, & 
Bryant, 2010) Biomarker studies have shown that increasing ER expression was associated 
with increasing CA125 response rate. (Smyth et al., 2007) We suggest that further studies are 
needed to study if PR expression may add value as a suitable biomarker to select patients 
for anti-hormonal therapy in ovarian cancer.  
7. Conclusions 
To conclude, oncogenic pathway profiling of advanced serous ovarian tumours revealed 
that it is difficult to estimate the true prognostic value of a pathway since there seems 
confounding of predictive factors. Despite these biases, with a meta-analysis approach of 6 
independent datasets generated on different micro-array platforms, we found that a PR and 
RAS activation score was associated with clinical outcome. Activation scores for ┚-Catenin, 
p63, E2F1 and PI3K were also associated with survival and were consistently correlated with 
three prognostic gene signatures.  
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